Elevated levels of IL-6 in IgA nephropathy patients are induced by an epigenetically driven mechanism triggered by viral and bacterial RNA

Sallustio Fabio[1], Claudia Curci[2], Maria Teresa Cimmarusti[2], Angela Picerno[1], Giuseppe De Palma[3], Carmen Sivo[2], Francesca Annese[2], Giulia Fontò[2], Alessandra Stasi[2], Francesco Pesce[2], Vincenzo Di Leo[2], Loreto Gesualdo[2].

1) Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy

2) Nephrology, Dialysis and Transplantation Unit, DETO, University "Aldo Moro" Bari, Italy

3) Institutional Biobank, Experimental Oncology and Biobank Management Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori Bari Giovanni Paolo II, Bari, Italy.

Corresponding author:

Fabio Sallustio, PhD; Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Piazza G. Cesare,11 70124 Bari, Italy; Tel./ Fax: 0039 080 5478878; Email: fabio.sallustio@uniba.it

ABSTRACT

Recently, several models have been proposed to describe the pathogenesis of Immunoglobulin A nephropathy (IgAN), and among them the multihit and the gut-microbiota.

Newly, the role of IL-6 in pathogenesis is becoming increasingly important but reason why levels of IL-6 are elevated in IgAN patients is not well understood. One attainable hypothesis on high levels of IL-6 in IgAN comes out from our recent whole genome DNA methylation screening in IgAN patients, that identified, among others, a hypermethylated region comprising Vault RNA 2-1 (VTRNA2-1), a non-coding RNA. Consistently, the VTRNA2-1 expression was found down-regulated in IgAN patients.

Here we confirm that VTRNA2-1 is low expressed in IgAN subjects compared to HS and we found that also in transplanted IgAN patients (TP-IgAN), compared to non-IgAN transplanted patients (TP), the VTRNA2-1 transcript was expressed at level very low. We found that in IgAN patients with downregulated VTRNA2-1, PKR is overactivated, coherently with the role of the VTRNA2-1 that binds to PKR and inhibits its phosphorylation. The loss of the VTRNA2-1 natural restrain caused the activation of CREB by PKR, a classical cAMP-inducible CRE-binding factor interacting with a region of the IL-6 promoter and leading to IL-6 production. We found higher CREB phosphorylation levels and IL-6 levels both in IgAN and in TP-IgAN patients.

Since PKR is normally activated by bacterial and viral RNA, we hypothesized that these microorganisms can further activate the PKR/CREB/IL-6 pathway leading to an excess of IL-6 production, explaining both the high levels of IL-6, both infection involvement in the disease, both cases of IgAN associated with COVID-19 infection and with COVID-19 RNA-vaccination.

Effectively, we found that both the RNA poly(I:C) and the COVID-19 RNA-vaccine stimulation significantly increase the IL-6 levels in IgAN patient PBMCs.

In conclusion, the discovery of the upregulated VTRNA2-1/PKR/CREB/IL-6 pathway in IgAN patients may provide novel approach to treat the disease and may be useful for development of

45 precision nephrology and personalized therapy, possibly by checking the VTRNA2-1 methylation
46 level in IgAN patients.
47
48
49

50 **INTRODUCTION**

51 Immunoglobulin A nephropathy (IgAN), also known as Berger's disease, is the most frequent primary
52 glomerulonephritis characterized by the presence of IgA immune complexes in the glomeruli (1). It
53 generally appears in the second and third decade of life, has a higher incidence in males and it is more
54 common in whites than in blacks with a higher prevalence in Asians than Caucasians(1).

55 Recently, a multihit model has been proposed to describe the pathogenesis of IgAN. In this model,
56 the first hit is given by the hypersecretion of deglycosylated IgA (Gd-IgA1)(2). In circulation, these
57 Gd-IgA1 are recognized and attacked by autoantibodies (second hit) and this process leads to the
58 formation of circulating immune complexes (third hit), some of which are deposited at the mesangial
59 level in the glomeruli(2). Kidney damage resulting from the deposition of the cells is characterized
60 by local inflammation, complement activation, cell proliferation, and finally fibrosis(3).

61 Moreover, in humans, the gut-associated lymphoid tissue (GALT) is the primary source of IgA, so
62 the pathogenesis of IgAN is related to gut homeostasis. Indeed, the intestinal–renal axis is important
63 in Berger's glomerulonephritis, where several factors (e.g. genetics(4,5), infections(6,7), and food
64 antigens (8) may play a role in the disease complex pathogenesis and provide novel therapeutic targets
65 to modify disease evolution.

66

67 These models explain the pathogenesis of IgAN caused by the production of aberrant IgA, but it is
68 believed further predisposing factors are present, including immunological, genetic, environmental,
69 or nutritional factors that can influence the pathogenesis and that could be useful for development of
70 precision nephrology and personalized therapy.

71 We have recently showed that IgAN patients have a higher frequency of intestinal-activated B cells
72 than healthy subjects (HS). IgAN patients had greater BAFF cytokine blood levels, which were linked
73 to higher levels of five microbiota metabolites, and high APRIL cytokine serum levels. In comparison
74 to HS, IgAN individuals had a larger number of circulating gut-homing (CCR9 β7 integrin) regulatory
75 B cells, memory B cells, and IgA memory B cells(9).

76 Moreover, several studies have shown the involvement of the IL-6 pathway in IgAN. Interleukin-6 is
77 essential for glomerular immunoglobulin A deposition and the development of renal pathology in
78 Cd37-deficient mice (10), Moreover, the proliferation-inducing ligand (APRIL) and IL-6 are
79 involved in the overproduction of aberrantly glycosylated IgA. In mice, the APRIL silencing blocked
80 the overproduction of Gd-IgA1 induced by IL-6 and, conversely, neutralizing IL-6, the production of
81 Gd-IgA1 was reduced(11). Interestingly, the mycotoxins deoxynivalenol (DON) prolonged exposure
82 cause the expansion of IgA secreting B cells by activating macrophages and T cells. In mice it results
83 in the early stages of human IgA nephropathy(12,13) and the overproduction of inflammatory
84 interleukins such as IL-6(14), which in turn induces upregulation of IgA.
85
86 However, to date, the biological mechanisms leading to the elevate IL6 levels in IgAN patients are
87 not clear. In a recent study, a whole-genome screening was performed for DNA methylation in $CD4^+$
88 T cells from IgAN patients, identifying three regions with altered methylation capable of influencing
89 the gene expression of genes involved in cell response and proliferation T $CD4^+$(15). In particular, a
90 hypermethylated region was identified comprising Vault RNA 2-1 (VTRNA2-1), a non-coding RNA
91 also known as the precursor of miR-886 (Pre-mi-RNA).
92
93 Here we studied the VTRNA2-1/PKR/CREB/IL-6 pathway showing that it is upregulated in IgAN
94 patients and that it is responsible for the elevated IL-6 levels characterizing the disease, thus providing
95 for the first time an explanation on the abnormal levels of this cytokine. We found that this pathway
96 is epigenetically controlled by VTRNA2-1 and triggered by bacterial and viral infections. It can
97 explain both the high levels of IL-6 and the correlation to mucosal infections. Finally, we showed
98 how the imoxin inhibitor, targeting this pathway, can reduce IL-6 secretion by PBMCs of IgAN
99 patients providing a new possible approach to treat the disease.
100
101

102 **RESULTS**

103

104 **VTRNA2-1 is downregulated in IgAN patients**

105 Recently, we showed that the non-coding RNA VTRNA2-1 was epigenetically downregulated in
106 IgAN patients(15). Since we hypothesize that it may be implicated in the pathway for the secretion
107 of IL-6, we further confirm the involvement of VTRNA2-1 in IgAN studying its expression in
108 PBMCs isolated from IgAN patients and healthy subjects.

109 VTRNA2-1 was strongly downregulated in IgAN patients compared to healthy subjects showing a
110 decrease of 30 fold ($p < 0.05$, Figure 1A). Moreover, recent clinical observations have shown that IL-
111 6 production is implicated in renal allograft rejection(16,17) and that cumulative risk of IgA
112 nephropathy recurrence increased after transplant and was associated with a 3.7-fold greater risk of
113 graft loss (17).

114 We therefore analysed the expression of VTRNA2-1 in PBMCs isolated from IgAN patients with
115 kidney transplant (T-IgAN) and in patients non-IgAN with kidney transplant (TP). Also in this case,
116 we found that the VTRNA2-1 was extremely downregulated in transplanted IgAN patients compared
117 to their controls ($p<0.0001$, fold change=100; Figure 1B), confirming that this modulation is a
118 characteristic of IgAN disease.

119



Figure 1. VTRNA2-1 expression in real-time PCR. (A)Real-time PCR of VTRNA2-1 transcript differentially expressed in PBMCs of IgAN and HS. (B) Real-time PCR of VTRNA2-1 transcript differentially expressed in PBMCs of T-IgAN and TP. Data are expressed as mean ± SEM, (* p-value < 0.05, ****p-value <0.001).

Downregualtion of VTRNA2-1 In IgAN patients lead to the increase in phosphorilated PKR.

VTRNA2-1 can inhibit PKR, an interferon-inducible and double-stranded RNA (dsRNA) dependent kinase, by binding to this protein and preventing its auto-phosphorylation(18). Thus, we studied whether in the IgAN patients with low levels of VTRNA2-1 the correspective upregulation of the PKR signalling was present. We measured the levels of the phosphorilated (pPKR) and of the total PKR and found that in IgAN patients the level of pPKR protein normalized on the total PKR was significantly increased compared to HS (FC 2.6; $p<0.05$; Fig. 2A). At the same manner, also in T-IgAN we found the doubling of pPKR levels compared to TP (FC 2, $p<0.05$; Fig. 2B).

To confirm that the incerase in pPKR levels was due to the auto-phosphorylation induced by the lack of VTRNA2-1 and not by a different mechanism regulating the gene expression, we checked the PKR mRNA levels in IgAN patients and in HS. We found no significant differences between the two group

137 (Figure 2C). However, in T-IgAN compared to TP we found rather a decrease of the PKR transcripts

138 (Figure 2D, P<0.0001), making data of the pPKR increase even more meaningful.



139

140 **Figure 2. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated PKR**

141 (A) ELISA assay showed significantly increased level of phosphorylated PKR in IgAN patients respect to healthy

142 group (HS). (B) A strong increase in phospho-PKR levels was found in T-IgAN patients compared to TP group. (C)

143 Gene expression of PKR in IgAN patients and HS. (D) Gene expression of PKR in TP and T-IgAN patients. Data

144 are representative of 8 independent experiments (means ±SEM; * p-value < 0.05).

145

146

147 **Phosphorilation of PKR corresponds to CREB activation in IgAN patients**

148 In mice pPKR induced the Cyclic adenosine monophosphate (AMP) response element-binding

149 protein (CREB) activation by increasing its phosphorilation (12). We studied whether in IgAN

150 patients CREB phosphorilation levels were higher compared to HS. A significant 3-fold increase of

151 pCREB levels was found in IgAN patients compared to HS (p<0.01; Fig. 3 A). Also in T-IgAN

152 pCREB levels were significantly increase compared to TP, even if to less extent (1.67 fold, p<0.01;

153 Fig. 3B). However, no significant difference in CREB gene expression was present among IgAN

154 patients and HS (Figure 3C), nor in TX compared to T-IgAN (Fig. 3D), corroborating the data of
155 CREB phosphorilation in IgAN patients.



156

157 **Figure 3. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated CREB** (A) The assay
158 revealed systemic activation of CREB (phospho-Thr305-CREB) in IgAN group compared to healthy subjects (HS).
159 (B) CREB phosphorylation was also significantly increased in T-IgAN patients compared to transplanted patients
160 without IgAN disease. (C) Gene expression of CREB in IgAN patients and HS. (D) Gene expression of CREB in
161 TP and T-IgAN patients. Data are representative of 8 independent experiments (means ±SEM; * p-value < 0.05,
162 ****p-value <0.001).

163

164 **CREB activation by phosphorilation leads to IL-6 incerase in IgAN patients.**

165 Since several studies showed that CREB activation may lead to IL-6 expression(20–24), we analyzed
166 the IL-6 levels secreted by PBMCs in our IgAN patient groups. IL-6 levels showed a statistically
167 significant increase in IgAN patients compared to HS (p<0.05; Fig. 4A). In T-IgAN compared to TP
168 a tendence in increased levels of IL-6 was found, even if it is not significant (Fig. 4B). Both the levels
169 of pCREB and pPKR significantly correlated with IL-6 levels in IgAN patients (r=0.97, p= 0.0006

170 and r=0.89, p=0.0064, respectively), indicating that the high levels of this cytokine are due to the

171 VTRNA2-1/pPKR/pCREB signalling epigenetically regulated (Figure 4C-D).

172



173

174

175 **Figure 4. VTRNA2-1/PKR/CREB activated pathway leads to elevated IL-6 secretion in IgAN patients** (A)

176 ELISA assay showed significant increased levels of IL-6 in IgAN patients with VTRNA2-1/PKR/CREB activated

177 pathway respect to healthy group. (B) An IL-6 increase was found in T-IgAN patients with VTRNA2-1/PKR/CREB

178 activated pathway compared to TP group, even if not statistically significant. Both the levels of pPKR (C) and

179 pCREB (D) significantly correlated with IL-6 levels in IgAN patients (r=0.97, p= 0.0006 and r=0.89, p=0.0064,

180 respectively). Data are representative of 8 independent experiments (means ±SEM; * p-value < 0.05).

181

182

183

184 **Bacterial RNA viral RNA or COVID vaccine stimulation increase and imoxin decrease IL-6**
185 **secretion by PBMCs from HS and IgAN patients.**

186 The biological effect of triggering or blocking the PKR/CREB/IL-6 pathway on PBMCs from IgAN
187 patients and HS was studied. Since PKR can be activated by viral or bacterial RNA (25,26) (27,28)
188 lymphocytes were transfected with synthetic polyinosinic:polycytidylic acid (poly(I:C)), which
189 mimics viral dsRNA or with a COVID RNA vaccine. We found that the poly(I:C) and the vaccine
190 stimulation significantly increased the IL-6 secretion by PBMCs from both HS and IgAN patients
191 (Figure 5, $p<0.05$).

192 We then studied the effect of the PKR inhibitor imoxin on the IL-6 secretion. When IgAN patients
193 and HS PBMCs were stimulated with 1 µM imoxin, a drastic decrease in IL-6 levels was obtained
194 (Figure 6 A-B, $p<0.05$). Interestingly, Imoxin was effective also when used 48h after stimulation with
195 poly(I:C) (Figure 6C).



196

197 **Figure 5. poly(I:C) and COVID vaccine stimulation increase and imoxin decrease IL-6 secretion by PBMCs**
198 **from HS and IgAN patients.**

199 ELISA assay showing that the poly(I:C) (A) and the COVID vaccine (B) stimulation significantly increased the IL-
200 6 secretion by PBMCs from HS. (C) ELISA assay showing that imoxin (C16) significantly decrease the IL-6

201 secretion by PBMCs from HS. (D) ELISA assay showing that imoxin (C16) significantly decrease the IL-6 secretion

202 by PBMCs from IgAN patients.



203

204 **Figure 6. PKR Inhibitor Imoxin decrease the IL-6 secretion even following viral RNA triggering**

205 ELISA assay showing that imoxin (C16) significantly decrease the IL-6 secretion in PBMCS from HS, even when

206 used 48h after stimulation with poly(I:C).

207

208 **DISCUSSION**

209 The exact immunopathogenic mechanisms underlying IgAN are poorly understood. The original
210 multi-hit pathogenesis model integrates findings from studies on galactose-deficient IgA1, anti-
211 glycan response, formation, deposition of IgA1-containing immune complexes, and mechanisms of
212 immune complex-mediated tissue injury. Very recently the role of Il-6 in IgAN pathogenesis is
213 becoming increasingly important(29–33), even if the reason why levels of IL-6 are elevated in IgAN
214 patients is not well understood.

215 It selectively increases production of galactose-deficient IgA1 in IgA1-secreting cells from patients
216 with IgA nephropathy(29,30) and IL6-/- mice displayed no glomerular IgA deposition and were
217 protected from exacerbated renal failure following lipopolysaccharide treatment(32). Interestingly,
218 IL-6 signalling seems to be involved in this complex intestinal immune network particularly in
219 mediating the production of Gd-IgA(10,34).

220 One attainable hypothesis on high levels of IL-6 in IgAN comes out from our recent whole genome
221 DNA methylation screening in IgAN patients, that identified, among others, three regions with altered
222 DNA methylation capable of influencing the expression of genes involved in the response and
223 proliferation of T and B cells (15). We identified a hypermethylated region encompassing Vault
224 RNA 2-1 (VTRNA2-1), a non-coding RNA also known as precursor of miR-886 (pre-mi-RNA).
225 Consistently, the VTRNA2-1 expression was found down-regulated in IgAN patients (15).

226 Here we confirm that VTRNA2-1 is lower expressed in IgAN subjects compared to HS and we found
227 that also in transplanted IgAN patients compared to non IgAN transplanted patients the VTRNA2-1
228 transcript was expressed at level very low. The VTRNA2-1 gene produces an RNA polymerase III
229 transcript that resembles both a component of the ribonucleoprotein vault particle and a pre-
230 microRNA. However, the RNA product does not function as a vault or microRNA; rather, it acts as
231 a direct inhibitor of protein kinase R (also known as eukaryotic translation initiation factor 2-alpha
232 kinase 2, EIF2AK2), and thereby plays an important role in the regulation of cell growth. This gene
233 is nearby a differentially methylated region (DMR), it is imprinted and may show allele-specific

234 expression. VTRNA2-1 is a metastable epiallele with accumulating evidence that methylation at this
235 region is heritable, modifiable, and associated with disease including risk and progression of
236 cancer(35).
237 We found that, in IgAN patients with downregulated VTRNA2-1, PKR is overactivated, coherently
238 with the role of the VTRNA2-1 that binds to PKR and inhibits its phosphorylation (36). The loss of
239 this natural restrain causes the activation of CREB, a classical cAMP-inducible CRE-binding factor
240 interacting with a region of the IL-6 promoter (that is known as CRE-like sequence), leading to IL-6
241 production (20–24).
242
243 The discovery of the upregulation of the PKR/CREB/IL-6 in IgAN patients is very suggestive. PKR
244 is normally activated by double-strand bacterial(25,26) and single-strand viral (27,28) RNA and has
245 long been recognized as a key mediator of the innate immunity response to viral infection. Expression
246 of latent PKR is induced by interferon and it is activated upon binding to viral RNA containing duplex
247 regions to undergo autophosphorylation. The data showing that, in IgAN patients, the PKR signalling
248 is already activated due to their epigenetic background could explain why the disease has traditionally
249 been considered as correlated to mucosal infections because of the clinical manifestation of hematuria
250 following upper respiratory tract microbes challenge(37,38). Bacterial and viral RNA may effectively
251 further activate the PKR/CREB/IL-6 pathway leading to an excess of IL-6 production (Figure 7).
252 Moreover, recently it has been found that, upon stimulation in vitro, the Epstein-Barr virus (EBV)-
253 infected IgA+ B cells secreted Gd-IgA1 and that B cells and their IgA+ subpopulation in PBMCs of
254 IgAN patients displayed a significantly higher frequency of EBV infection than did cells of the same
255 phenotype from non-IgAN patients(39). Interestingly, a different study very recently showed that
256 PKR is regulated by EBV RNA(40).
257 This kind of mechanism, driven by the epigenetic silencing of VTRNA2-1, may therefore explain
258 both the high levels of IL-6, and infection involvement in the disease, and recent data showing
259 microbiota involvment in IgAN (9) (41) (42). Our hypothesis is also supported by studies showing

260 that synthetic double-stranded RNA poly(I:C) stimulation promotes IgA class-switch recombination
261 and BAFF productions in tonsil mononuclear cells via the TLR3 pathway(43). Effectively, we
262 showed that both the RNA poly(I:C) and the COVID-19 RNA-vaccine stimulation significantly
263 increase the IL-6 levels in IgAN patient PBMCs.
264 Also, recent data showing 13 IgAN cases associated with COVID-19 infection and 4 cases of IgAN
265 following COVID-19 RNA-vaccination(44) may be clearly explained by our discovered mechanism
266 trough the PKR activation by RNA (Figure 7).
267
268 The PKR/CREB/IL-6 pathway may be very important also in the setting of renal transplantation. We
269 found that this pathway is upregulated also in IgAN transplanted patients. Recent studies showed that
270 the cumulative risk of IgA nephropathy recurrence increases after transplant and is associated with a
271 3.7-fold greater risk of graft loss(45). Besides, evidence suggests that IL-6 may play an important
272 role in donor-specific antibodies generation and chronic active antibody-mediated rejection and that
273 the treatment with an anti-IL-6 receptor monoclonal antibody may represent a novel approach for
274 chronic antibody-mediated rejection and transplant glomerulopathy, stabilizing allograft function and
275 extend patient lives (17).
276
277 Finally, we showed that the IL-6 secretion can be reduced by the PKR inhibitor imoxin (Figure 7).
278 This drug also known as C16 or imidazole, has shown beneficial effects on cell cultures and in vivo
279 in animal models for numerous conditions, such as improvement in inflammation, oxidative stress,
280 diabetes, suppression of tumor proliferation and in the control of hypertension. However, in light of
281 our results, it may be considered as a possible therapeutic drug also in IgAN (46). Interestingly, in
282 mice dietary exposure to the common foodborne mycotoxin deoxynivalenol (DON) upregulates
283 serum immunoglobulin A (IgA) and IL-6 miming IgAN and activating PKR/CREB/IL-6 pathway.
284 The dietary omega-3 fatty acids can invert these processes and ameliorate DON-induced IgA
285 nephropathy (12,13).

In conclusion, the discovery of the upregulated VTRNA2-1/PKR/CREB/IL-6 pathway in IgAN patients may provide novel approach to treat the disease and may be useful for development of precision nephrology and personalized therapy.



294 **Figure 7. The involvment of PKR/CREB/IL-6 pathway in IgAn patients and its modulation.**

295 In IgAN patients the PKR/CREB/IL-6 pathway is overexpressed and lead to the IL-6 secretion by patient PBMCs.
296 Yhe pathway is modulated by the hypermetilated that is low expressed can not inhibit PKR phosphorylation. As a
297 consequence PKR is hyperphosphorylated and, in tur, actives phosphorylation of CREB kinase. Posho CREB
298 (pCREB) interacts with a region of the IL-6 promoter and leads to high levels of IL-6 production. PKR is also
299 induced by bacterial and viral RNA, thus transfection with synthetic polyinosinic:polycytidylic acid (poly(I:C)) and
300 COVID-19 vaccine increase IL-6 levels in IgAN patients. However, the drug Imoxin is a PKR inhibitor, that
301 prevents PKR phosphorylation and as a consequence inhibits the PKR/CREB/IL-6 pathway, with a significantly
302 decrease of IL-6 secretion. The discovery of the involvement of this pathway in IgAN and of the beneficial effects
303 of Imoxin provide a novel approach to treat the disease and may be useful for the development of precision
304 nephrology and personalized therapy.

305

306

307

308

309

310

311

312

313 **MATERIALS AND METHODS**

314

315 **Study design and patients**

316 The study was carried out in accordance with the Helsinki Declaration and the European Guidelines
317 for Good Clinical Practice and approved by our institutional ethics review. A total of 15 biopsy-
318 proven IgAN patients, 22 IgAN subjects with kidney transplant (T-IgAN), 14 patients transplanted
319 for causes other than IgAN (TP), and 10 Healthy subjects (HS) from south Italy were included in the
320 study after providing their written informed consent.

321 PBMCs were isolated by gradient centrifugation with Ficoll-Hypaque (Euroclone, Italy) from
322 heparinized venous blood from patients and HS. PBMCs were cultured in RPMI 1640 (Euroclone)
323 supplemented with 10% Fetal Bovine Serum (Euroclone), 100U/mL Penicillin/Streptomycin
324 (Euroclone), 4mMGlutamine (Euroclone), 10 mM Hepes (Sigma), 0.1 mM non-essential amino acids
325 (Euroclone), 1mM sodium pyruvate and 50 U/mL, rhIL-2.

326

327 **RNA extraction and real time-PCR expression of VTRNA2-1, CREB and PKR**

328 Total RNA were isolated from PBMCs of IgAN, T-IgAN, TP and HS using RNeasy Mini Kit (Qiagen,
329 Hilden, Germany) according to the manufacturer's instruction and quantified by NanoDrop One
330 Spectrophotometer (thermoFisher Scientific). Total RNA was retro-transcribed using the miScript II
331 RT Kit with iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA)following the manufacturer's
332 instructions.

333 Real Time-PCR was performed on a StepOne Plus instrument (Applied Biosystems) by using
334 VTRNA2-1, PKR and CREB primers (Integrated DNA Technologies, Coralville,
335 IA,USA) GAPDH gene amplification was used as a reference standard to normalize the target signal.
336 Real Time-PCR was performed in triplicate, and relative expression was calculated using the $2^{-\Delta C_t}$
337 method.

338

339 **pPKR/pCREB/IL-6 pathway ELISA quantification**

340 Colorimetric Cell-Based ELISA assays were used to detect the levels of CREB/pCREB (CREB
341 (Phospho-Ser142) Aviva Systems Biology, USA), and PKR/pPKR (PKR (Phospho-Thr258) Aviva
342 Systems Biology, USA).

343 Briefly, PBMCs of HS, IgAN, T-IgAN and TP subjects were freshly isolated and seeded overnight
344 with RPMI medium at 37°C, 5% CO_2, in a 96-Well Cell Culture Clear-Bottom Microplate. The
345 ELISA assay protocols were executed following manufacturer instructions.

346 To determine IL-6 levels, PBMCs of HS, IgAN, T-IgAN and TP subjects, were freshly isolated and
347 seeded in a 96-Well Cell Culture Microplate supplemented with RPMI medium at 37°C, 5% CO_2.
348 After 48 h of culture, cells were collected and, centrifuged at 230 rpm for 15 minutes. Supernatant
349 were recovered and analysed using Human IL-6 Quantikine ELISA Kit (R&D Systems, USA),
350 following manufacturer's protocol.

351 Optical densities were determined using a microplate reader (programmable MPT reader model DV
352 990BV6; GDV, Italy) set to 450 nm.

353

354 **Transfection experiments**

355 PBMCs of HS and IgAN patients were seeded in 6-well plates at a density of 2 x 10^6 cells/cm^2 and
356 were incubated with specific medium. Xfect Transfection Reagent (Clontech,Takara bio, France) was
357 used to transfect 20 ug of Poly (I:C) (InvivoGen, Europe), a synthetic analogue of dsRNA, in PBMC
358 cells, according to manufacturer's instructions. Imoxin (Chem Cruz) was added to PBMCs at a
359 concentration of 1 μM. After two days of incubation with Poly (I:C) and/or Imoxin the secretion of
360 IL-6 levels by PBMCs were measured in the cell culture supernatants.

361

362 **Statistical Analysis**

363 Statistical analyses were performed using the Student's t-test, as appropriate. A p-value < 0.05 was
364 considered significant. Data are expressed as means ± SEM.

365 **REFERENCES**

366

367 1. Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. *Clinical Journal of the American Society*
368 *of Nephrology* (2017) **12**:677–686. doi: 10.2215/CJN.07420716

369 2. Suzuki H. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis. *Clinical and*
370 *Experimental Nephrology 2018 23:1* (2018) **23**:26–31. doi: 10.1007/S10157-018-1582-2

371 3. Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F,
372 Mestecky J, Gharavi AG, et al. The Pathophysiology of IgA Nephropathy. doi:
373 10.1681/ASN.2011050464

374 4. Sallustio F, Cox SN, Serino G, Curci C, Pesce F, De Palma G, Papagianni A, Kirmizis D,
375 Falchi M, Schena FP. Genome-wide scan identifies a copy number variable region at 3p21.1
376 that influences the TLR9 expression levels in IgA nephropathy patients. *European Journal of*
377 *Human Genetics 2015 23:7* (2014) **23**:940–948. doi: 10.1038/ejhg.2014.208

378 5. Castigli E, Scott S, Dedeoglu F, Bryce P, Jabara H, Bhan AK, Mizoguchi E, Geha RS. Impaired
379 IgA class switching in APRIL-deficient mice. *Proceedings of the National Academy of*
380 *Sciences* (2004) **101**:3903–3908. doi: 10.1073/PNAS.0307348101

381 6. Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash
382 S, Shapiro S, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved
383 in immunity against intestinal pathogens. *Nature Genetics 2014 46:11* (2014) **46**:1187–1196.
384 doi: 10.1038/ng.3118

385 7. Coppo R. The intestine–renal connection in IgA nephropathy. *Nephrology Dialysis*
386 *Transplantation* (2015) **30**:360–366. doi: 10.1093/NDT/GFU343

387 8. Papista C, Lechner S, Mkaddem S Ben, LeStang M-B, Abbad L, Bex-Coudrat J, Pillebout E,
388 Chemouny JM, Jablonski M, Flamant M, et al. Gluten exacerbates IgA nephropathy in
389 humanized mice through gliadin–CD89 interaction. *Kidney International* (2015) **88**:276–285.
390 doi: 10.1038/KI.2015.94

391 9. Sallustio F, Curci C, Chaoul N, Fontò G, Lauriero G, Picerno A, Divella C, di Leo V, de
392 Angelis M, ben Mkaddem S, et al. High levels of gut-homing immunoglobulin A-positive+B
393 lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in
394 immunoglobulin A nephropathy patients. *Nephrology, dialysis, transplantation : official*
395 *publication of the European Dialysis and Transplant Association - European Renal*
396 *Association* (2020) doi: 10.1093/ndt/gfaa264
397 10. Rops ALWMM, Jansen E, van der Schaaf A, Pieterse E, Rother N, Hofstra J, Dijkman HBPM,
398 van de Logt AE, Wetzels J, van der Vlag J, et al. Interleukin-6 is essential for glomerular
399 immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice.
400 *Kidney International* (2018) **93**:1356–1366. doi: 10.1016/J.KINT.2018.01.005
401 11. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation
402 induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA
403 nephropathy. *Kidney International* (2020) **97**:340–349. doi: 10.1016/J.KINT.2019.08.022
404 12. Pestka JJ. Deoxynivalenol-induced IgA production and IgA nephropathy-aberrant mucosal
405 immune response with systemic repercussions. *Toxicology Letters* (2003) **140–141**:287–295.
406 doi: 10.1016/S0378-4274(03)00024-9
407 13. Shi Y, Pestka JJ. Mechanisms for suppression of interleukin-6 expression in peritoneal
408 macrophages from docosahexaenoic acid-fed mice. *Journal of Nutritional Biochemistry* (2009)
409 **20**:358–368. doi: 10.1016/J.JNUTBIO.2008.04.006
410 14. Yan D, Zhou HR, Brooks KH, Pestka JJ. Potential role of IL-5 and IL-6 in enhanced IgA
411 secretion by Peyer's patch cells isolated from mice acutely exposed to vomitoxin. *Toxicology*
412 (1997) **122**:145–158. doi: 10.1016/S0300-483X(97)00087-5
413 15. Sallustio F, Serino G, Cox SN, Gassa AD, Curci C, De Palma G, Banelli B, Zaza G, Romani
414 M, Schena FP. Aberrantly methylated DNA regions lead to low activation of CD4+ T-cells in
415 IgA nephropathy. *Clinical Science* (2016) **130**:733–746. doi: 10.1042/CS20150711

416 16. Kim I, Wu G, Chai N, Klein AS, Jordan S. Anti-interleukin 6 receptor antibodies attenuate
417 antibody recall responses in a mouse model of allosensitization. *Transplantation* (2014)
418 **98**:1262–70. doi: 10.1097/TP.0000000000000437
419 17. Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, Kim I, Louie S, Kang A, Peng A, et
420 al. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential
421 Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-
422 Sensitized Renal Allograft Recipients. *American journal of transplantation : official journal*
423 *of the American Society of Transplantation and the American Society of Transplant Surgeons*
424 (2017) **17**:2381–2389. doi: 10.1111/ajt.14228
425 18. Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY, Bang JY, Park HS, Leelayuwat
426 C, Lee YS. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with
427 PKR and modulates its activity. *RNA* (2011) **17**:1076–1089. doi: 10.1261/rna.2701111
428 19. Shi Y, Pestka JJ. Mechanisms for suppression of interleukin-6 expression in peritoneal
429 macrophages from docosahexaenoic acid-fed mice. *The Journal of nutritional biochemistry*
430 (2009) **20**:358–68. doi: 10.1016/j.jnutbio.2008.04.006
431 20. Spooren A, Kooijman R, Lintermans B, van Craenenbroeck K, Vermeulen L, Haegeman G,
432 Gerlo S. Cooperation of NFkappaB and CREB to induce synergistic IL-6 expression in
433 astrocytes. *Cellular signalling* (2010) **22**:871–81. doi: 10.1016/j.cellsig.2010.01.018
434 21. Ishizu A, Abe A, Miyatake Y, Baba T, Iinuma C, Tomaru U, Yoshiki T. Cyclic AMP response
435 element-binding protein is implicated in IL-6 production from arthritic synovial cells. *Modern*
436 *rheumatology* (2010) **20**:134–8. doi: 10.1007/s10165-009-0245-2
437 22. Yang R, Lin Q, Gao HB, Zhang P. Stress-related hormone norepinephrine induces interleukin-
438 6 expression in GES-1 cells. *Brazilian journal of medical and biological research = Revista*
439 *brasileira de pesquisas medicas e biologicas* (2014) **47**:101–9. doi: 10.1590/1414-
440 431X20133346

441 23. Luo Y, Zheng SG. Hall of Fame among Pro-inflammatory Cytokines: Interleukin-6 Gene and
442 Its Transcriptional Regulation Mechanisms. *Frontiers in Immunology* (2016) **7**:604. doi:
443 10.3389/fimmu.2016.00604
444 24. Dendorfer U, Oettgen P, Libermann TA. Multiple regulatory elements in the interleukin-6 gene
445 mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. *Molecular and*
446 *cellular biology* (1994) **14**:4443–54. doi: 10.1128/mcb.14.7.4443-4454.1994
447 25. Bleiblo F, Michael P, Brabant D, Ramana C v., Tai T, Saleh M, Parrillo JE, Kumar A, Kumar
448 A. Bacterial RNA induces myocyte cellular dysfunction through the activation of PKR.
449 *Journal of Thoracic Disease* (2012) **4**: doi: 10.3978/J.ISSN.2072-1439.2012.01.07
450 26. Hull CM, Bevilacqua PC. Mechanistic Analysis of Activation of the Innate Immune Sensor
451 PKR by Bacterial RNA. *Journal of molecular biology* (2015) **427**:3501–3515. doi:
452 10.1016/j.jmb.2015.05.018
453 27. García MA, Meurs EF, Esteban M. The dsRNA protein kinase PKR: virus and cell control.
454 *Biochimie* (2007) **89**:799–811. doi: 10.1016/j.biochi.2007.03.001
455 28. Pindel A, Sadler A. The role of protein kinase R in the interferon response. *Journal of*
456 *interferon & cytokine research : the official journal of the International Society for Interferon*
457 *and Cytokine Research* (2011) **31**:59–70. doi: 10.1089/jir.2010.0099
458 29. Zhang J, Mi Y, Zhou R, Liu Z, Huang B, Guo R, Wang P, Lu Y, Zhou Y, Quan S. The TLR4-
459 MyD88-NF-κB pathway is involved in sIgA-mediated IgA nephropathy. *Journal of*
460 *nephrology* (2020) **33**:1251–1261. doi: 10.1007/s40620-020-00722-3
461 30. Yamada K, Huang Z-Q, Raska M, Reily C, Anderson JC, Suzuki H, Ueda H, Moldoveanu Z,
462 Kiryluk K, Suzuki Y, et al. Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen
463 Production in IgA Nephropathy. *Kidney International Reports* (2017) **2**:1194–1207. doi:
464 10.1016/j.ekir.2017.07.002

465 31. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation
466 induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA
467 nephropathy. *Kidney International* (2020) doi: 10.1016/j.kint.2019.08.022
468 32. Rops ALWMM, Jansen E, van der Schaaf A, Pieterse E, Rother N, Hofstra J, Dijkman HBPM,
469 van de Logt AE, Wetzels J, van der Vlag J, et al. Interleukin-6 is essential for glomerular
470 immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice.
471 *Kidney International* (2018) **93**:1356–1366. doi: 10.1016/j.kint.2018.01.005
472 33. Si R, Zhao P, Yu Z, Qu Z, Sun W, Li T, Jiang Y. Increased Non-switched Memory B Cells are
473 Associated with Plasmablasts, Serum IL-6 Levels and Renal Functional Impairments in IgAN
474 Patients. *Immunological Investigations* (2020) doi: 10.1080/08820139.2019.1683026
475 34. Makita Y, Suzuki H, Kano T, Takahata A, Julian BA, Novak J, Suzuki Y. TLR9 activation
476 induces aberrant IgA glycosylation via APRIL- and IL-6–mediated pathways in IgA
477 nephropathy. *Kidney International* (2020) **97**:340–349. doi: 10.1016/J.KINT.2019.08.022
478 35. Dugué P-A, Yu C, McKay T, Wong EM, Joo JE, Tsimiklis H, Hammet F, Mahmoodi M, Theys
479 D, kConFab, et al. VTRNA2-1: Genetic Variation, Heritable Methylation and Disease
480 Association. *International Journal of Molecular Sciences* (2021) **22**:2535. doi:
481 10.3390/ijms22052535
482 36. Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang G-Y, Bang JY, Park HS, Leelayuwat
483 C, Lee YS. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with
484 PKR and modulates its activity. *RNA* (2011) **17**:1076–1089. doi: 10.1261/RNA.2701111
485 37. He J-W, Zhou X-J, Lv J-C, Zhang H. Perspectives on how mucosal immune responses,
486 infections and gut microbiome shape IgA nephropathy and future therapies. *Theranostics*
487 (2020) **10**:11462–11478. doi: 10.7150/thno.49778
488 38. Rollino C, Vischini G, Coppo R. IgA nephropathy and infections. *Journal of Nephrology*
489 (2016) **29**:463–468. doi: 10.1007/s40620-016-0265-x

490 39. Zachova K, Kosztyu P, Zadrazil J, Matousovic K, Vondrak K, Hubacek P, Julian BA,
491 Moldoveanu Z, Novak Z, Kostovcikova K, et al. Role of Epstein-Barr Virus in Pathogenesis
492 and Racial Distribution of IgA Nephropathy. *Frontiers in Immunology* (2020) **11**:267. doi:
493 10.3389/fimmu.2020.00267
494 40. Zerbe CM, Cole JL. Regulation of Protein Kinase R by Epstein-Barr Virus EBER1 RNA.
495 *Biochemistry* (2020) **59**:1252–1260. doi: 10.1021/acs.biochem.0c00088
496 41. He JW, Zhou XJ, Lv JC, Zhang H. Perspectives on how mucosal immune responses, infections
497 and gut microbiome shape iga nephropathy and future therapies. *Theranostics* (2020)
498 **10**:11462–11478. doi: 10.7150/THNO.49778
499 42. Angelis M De, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, Gozzi G,
500 Serrazanetti D, Dalfino G, Gobbetti M, et al. Microbiota and Metabolome Associated with
501 Immunoglobulin A Nephropathy (IgAN). *PLOS ONE* (2014) **9**:e99006. doi:
502 10.1371/JOURNAL.PONE.0099006
503 43. He L, Peng X, Wang J, Tang C, Zhou X, Liu H, Liu F, Sun L, Peng Y. Synthetic double-
504 stranded RNA Poly(I:C) aggravates IgA nephropathy by triggering IgA class switching
505 recombination through the TLR3-BAFF axis. *American Journal of Nephrology* (2015)
506 **42**:185–197. doi: 10.1159/000440819
507 44. Farooq H, Aemaz Ur Rehman M, Asmar A, Asif S, Mushtaq A, Qureshi MA. The pathogenesis
508 of COVID-19-induced IgA nephropathy and IgA vasculitis: A systematic review. *Journal of*
509 *Taibah University Medical Sciences* (2021) doi: 10.1016/j.jtumed.2021.08.012
510 45. Uffing A, Pérez-Saéz MJ, Jouve T, Bugnazet M, Malvezzi P, Muhsin SA, Lafargue M-C,
511 Reindl-Schwaighofer R, Morlock A, Oberbauer R, et al. Recurrence of IgA Nephropathy after
512 Kidney Transplantation in Adults. *Clinical journal of the American Society of Nephrology :*
513 *CJASN* (2021) **16**:1247–1255. doi: 10.2215/CJN.00910121

46. Kalra J, Dasari D, Bhat A, Mangali S, Goyal SG, Jadhav KB, Dhar A. PKR inhibitor imoxin prevents hypertension, endothelial dysfunction and cardiac and vascular remodelling in L-NAME-treated rats. *Life Sciences* (2020) **262**: doi: 10.1016/J.LFS.2020.118436

525 **FIGURE LEGENDS**

526

527 **Figure 1. VTRNA2-1 expression in real-time PCR.** (A)Real-time PCR of VTRNA2-1 transcript
528 differentially expressed in PBMCs of IgAN and HS. (B) Real-time PCR of VTRNA2-1 transcript
529 differentially expressed in PBMCs of T-IgAN and TP. Data are expressed as mean ± SEM, (* p-value
530 < 0.05, ****p-value <0.001).

531

532 **Figure 2. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated PKR**
533 (A) ELISA assay showed significantly increased level of phosphorylated PKR in IgAN patients
534 respect to healthy group (HS). (B) A strong increase in phospho-PKR levels was found in T-IgAN
535 patients compared to TP group. (C) Gene expression of PKR in IgAN patients and HS. (D) Gene
536 expression of PKR in TP and T-IgAN patients. Data are representative of 8 independent experiments
537 (means ±SEM; * p-value < 0.05).

538
539

540 **Figure 3. IgAN patients with low VTRNA2-1 showed elevated levels of phosphorylated CREB**
541 (A) The assay revealed systemic activation of CREB (phospho-Thr305-CREB) in IgAN group
542 compared to healthy subjects (HS). (B) CREB phosphorylation was also significantly increased in T-
543 IgAN patients compared to transplanted patients without IgAN disease. (C) Gene expression of
544 CREB in IgAN patients and HS. (D) Gene expression of CREB in TP and T-IgAN patients. Data are
545 representative of 8 independent experiments (means ±SEM; * p-value < 0.05, ****p-value <0.001).

546

547 **Figure 4. VTRNA2-1/PKR/CREB activated pathway leads to elevated IL-6 secretion in IgAN**
548 **patients** (A) ELISA assay showed significant increased levels of IL-6 in IgAN patients with
549 VTRNA2-1/PKR/CREB activated pathway respect to healthy group. (B) An IL-6 increase was found
550 in T-IgAN patients with VTRNA2-1/PKR/CREB activated pathway compared to TP group, even if

551 not statistically significant. Both the levels of pPKR (C) and pCREB (D) significantly correlated with
552 IL-6 levels in IgAN patients (r=0.97, p= 0.0006 and r=0.89, p=0.0064, respectively). Data are
553 representative of 8 independent experiments (means ±SEM; * p-value < 0.05).
554
555 **Figure 5. poly(I:C) and COVID vaccine stimulation increase and imoxin decrease IL-6**
556 **secretion by PBMCs from HS and IgAN patients.**
557 ELISA assay showing that the poly(I:C) (A) and the COVID vaccine (B) stimulation significantly
558 increased the IL-6 secretion by PBMCs from HS. (C) ELISA assay showing that imoxin (C16)
559 significantly decrease the IL-6 secretion by PBMCs from HS. (D) ELISA assay showing that imoxin
560 (C16) significantly decrease the IL-6 secretion by PBMCs from IgAN patients.
561
562 **Figure 6. PKR Inhibitor Imoxin decrease the IL-6 secretion even following viral RNA triggering**
563 ELISA assay showing that imoxin (C16) significantly decrease the IL-6 secretion in PBMCS from
564 HS, even when used 48h after stimulation with poly(I:C).
565
566